Infant Bacterial Therapeutics AB (publ) reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported net loss was SEK 28.82 million compared to net income of SEK 1.65 million a year ago. Basic loss per share from continuing operations was SEK 2.57 compared to basic earnings per share from continuing operations of SEK 0.15 a year ago.
For the six months, net loss was SEK 51.29 million compared to SEK 17.55 million a year ago. Basic loss per share from continuing operations was SEK 4.57 compared to SEK 1.56 a year ago.